Canakinumab Effective as First-Line Drug for Systemic Juvenile Idiopathic Arthritis Without Steroids
VIENNA — The interleukin 1 receptor antagonist (IL-1RA) canakinumab provided control of systemic juvenile idiopathic arthritis (sJIA) without the use of glucocorticoids for up to a year in most study ...
The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...
The government has approved new reimbursement rules enabling patients with advanced non-small cell lung cancer (NSCLC) to use ...
HONG KONG, Nov. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) announced that its first-in-class bispecific antibody, ivonescimab (PD-1/VEGF bispecific antibody), in combination with chemotherapy for ...
2024 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Middle East Daily-- New research on Heart Disorders and Diseases - Heart Attack is the subject of a report. According to news reporting ...
CHICAGO — Can spotting an emerging ESR1 mutation early and changing first-line drugs before progression improve outcomes in patients with hormone receptor (HR)–positive, human epidermal growth factor ...
BARCELONA -- Rheumatoid arthritis (RA) patients were exceedingly unlikely to develop refractory disease when their first medical therapy was a tumor necrosis factor (TNF) inhibitor, a researcher ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback